CannabisNewsWire
Editorial Coverage: The emergence of a legal recreational
cannabis sector has drawn attention away from the medical cannabis
market. However, many companies continue to move forward in this
strong sector, benefiting from extensive research and development
work. PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB:
PRVCF) (FSE: 18H) is developing new cannabis-based
medicines and delivery systems through partnership with researchers
in Australia. Invictus MD Strategies Corporation (TSX-V:
GENE) (OTC: IVITF) has created a network of profitable
growing facilities that allowed the company to pay out a
million-dollar dividend in 2016, the first dividend payout by a
Canadian cannabis company, and Radient Technologies, Inc.
(TSX-V: RTI) is partnering with cannabis companies to
produce medical cannabis extracts. Already the owner of a large
growing facility, WeedMD, Inc. (TSX-V: WMD) is in
the process of creating 610,000 square feet of greenhouse space
that will increase its cannabis production from 1,500kg to 33,000kg
over two phases of expansion. Wildflower Marijuana, Inc.
(SUN: CNX) sells a range of cannabis-based products,
including vaporizers and soap, and is set to expand in the
lucrative California market through new licenses in Los
Angeles.
Recreational Cannabis’s Big Brother
A lot of attention in the cannabis industry is currently focused
on the recreational market. A few nations and states, most notably
Canada and California, have legalized recreational cannabis or are
on the road to legalization. It’s a huge deal commercially, as
companies prepare to exploit new markets. But in the background,
the medical sector continues to make leaps forward in cannabis
use.
Despite tight restrictions limiting research, a number of
different medical benefits from cannabis have already been found.
Best known are its use in managing chronic pain and alleviating the
nausea and vomiting that follow chemotherapy. Some evidence
indicates it might also be effective in dealing with neurological
problems, including multiple sclerosis and epilepsy. Scientists are
also exploring the use of cannabis in treating HIV and AIDS
patients, as well as those suffering posttraumatic stress disorder
and a range of other ailments. With so much potential, it’s little
wonder that medical cannabis companies are examining every
opportunity to leverage their presence in the market.
Prevention, Not Just Cure
PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB:
PRVCF) (FSE: 18H) is among the companies committed to
researching and developing new cannabis-based treatments.
Founded in 2015, PreveCeutical is the creation of Stephen and
Kimberly Van Deventer. Entrepreneurs with extensive experience in
venture capital and business development, they have been working
together since 2009. As the minds behind Cornerstone Global
Partners, they supported the emergence of other companies with
significant presence in the medical cannabis sector.
The Van Deventers’ involvement in this sector peaked their
interest in health and wellness. They started looking into how they
could use their business skills in offering new treatments to
health-conscious consumers. Their aim was to combine scientific
research with the benefits of natural remedies in order to provide
the best of both worlds. PreveCeutical was founded to support this
objective, with a focus on preventive medicine, as reflected in its
name.
PreveCeutical has shown a strong commitment to working with
researchers, teaming up with research centers to develop new and
improved options for treatment. The company’s early work has
focused on acute problems such as cancer, obesity, Type 2 diabetes,
pain management and neurological disorders. That initial focus has
naturally led to work with cannabis because of the drug’s use in
tackling many of these ongoing ailments.
With its organic and nature identical products, PreveCeutical is
well oriented to appeal to consumers looking for ethically sourced
and effective treatments for diseases that other drugs are
struggling to treat.
Research into Cannabinoids
This week marks an important moment in PreveCeutical’s efforts
to improve healthcare through cannabis.
In fulfillment of an agreement announced earlier this year, the
first in a series of cannabis shipments has been shipped to the
Pharmacy Australia Centre for Excellence (PACE) at the University
of Queensland. The cannabis flowers and oils have been provided by
Aurora Cannabis, Inc. (TSX: ACB) (OTCQX: ACBFF) as part of a deal
with PreveCeutical. Grown within Canada’s carefully licensed and
increasingly sophisticated cannabis industry, the flowers and oils
will be used by PreveCeutical’s Australian researchers to create
and improve cannabis treatments.
Such international work is made complicated by the legal status
of cannabis, which varies significantly from one country to
another, and is tightly controlled even in territories where it can
be legally sold. For this one project, the companies have had to
obtain licenses for the export of cannabis from Canada and for that
cannabis to be brought into Australia for research purposes. Strict
standards have to be met for any sort of work on these
products.
PreveCeutical’s partnership with Aurora is an important one in
that it has the potential to bring considerable benefit for both
companies. As part of the deal, Aurora has received rights
including the option to either license resulting technology for
Canada and Australia or to opt for a royalty arrangement on product
sales (http://cnw.fm/8iRlH). This agreement shows faith in
PreveCeutical’s ability to provide effective, profitable treatments
based on its research.
“We see an important market for cannabis-based products that are
more narrowly targeted at specific therapeutic areas but that are
higher value add and being involved with initiatives such as
PreveCeutical’s is part of our strategy to gain access to these
types of products,” said Terry Booth, CEO of Aurora.
Expanding into Australia
To further support its research efforts in Australia,
PreveCeutical recently incorporated a new subsidiary in the country
(http://cnw.fm/3kcN2).
Led by its director of International Operations, Dr. Maher
Khaled, PreveCeutical (Australia) Pty Ltd will work closely with
the company’s chief research officer, Dr. Harry Parekh, to advance
the company’s goal of providing new health care options based on
rigorous research.
This expansion into Australia has been shaped by the country’s
strong academic and clinical research, as well as support from
government programs. The Australian government supports scientific
innovation through a range of programs and incentives, including a
research and development tax break. This provides a 43.5 percent
tax offset for eligible R&D activities, from which
PreveCeutical’s new subsidiary will benefit.
The company’s Australian research program is centered around the
Sol-gel system (http://cnw.fm/on3FQ). An innovative drug delivery
system, Sol-gel consists of medicine in liquid form that patients
administer via the nasal cavity. There, it forms a gel that stays
in place, slowly and steadily releasing active ingredients into the
bloodstream.
Sol-gel is ideally suited to deliver drugs targeting the brain.
When delivered by traditional methods such as pills and injections,
medications have to travel through complex bodily systems, slowing
down their arrival and resulting in the filtering out of much of
the medicine, thereby limiting the effectiveness of a given dose.
Sol-gel uses hydrogels and delivery close to the brain to bypass
many of these barriers.
Given cannabis’s potential in tackling pain and neurological
symptoms, many cannabis-based medicines are likely to target the
brain. With Sol-gel, PreveCeutical may be in a strong position to
provide one of the most effective delivery systems for a growing
class of drugs.
Using Cannabis as a Cure
Many companies are now involved in providing cannabis-based
medical treatments.
Invictus MD Strategies (TSX-V: GENE) (OTC:
IVITF) has a foothold in the Canadian cannabis market and
with an eye to future growth. Founded in 2014, the company has a
number of licensed growing facilities and over 250 acres of
property ready to be turned into cultivation space. The
one-million-dollar dividend it paid out in 2016 was the first
dividend payout by a Canadian cannabis company. With a platform
that includes ancillary products such as fertilizers and nutrients,
the company benefits from all elements of cannabis production.
Radient (TSX-V: RTI) specializes in the
extraction of compounds from biological materials through
microwave-assisted processing. This patented technology platform
lets the company extract the beneficial elements from all manner of
plants for use in food, pharmaceuticals, personal care and other
products. This includes working with cannabis growers to produce
cannabis extracts for medical use.
WeedMD (TSX-V: WMD) is a medical cannabis
company with a 26,0000-square-foot growing space in Ontario. A
producer of consistently high-quality cannabis, the company is
expanding as the Canadian cannabis market grows. The first phase of
an ambitious project to expand its growing facilities is currently
underway, with the aim of creating 610,000 square feet of
greenhouse space. This will increase the company’s cannabis
production from 1,500kg to 21,000kg per year, with a goal of
reaching 33,000kg with phase two of the expansion program.
Wildflower Marijuana (SUN: CNX) is focused on
providing cannabis health and wellness products for the U.S.
market. The company sells a range of products using cannabinoids,
including vaporizers, capsules and soap. Its recent acquisition of
retail and cultivation licenses in Los Angeles may allow the
company to expand in the increasingly lucrative California
market.
With so many companies providing a diverse range of products and
services, the medical cannabis market continues to go strong, even
as recreational cannabis draws the headlines.
For more information on PreveCeutical, visit
PreveCeutical
Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H).
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, CNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. CNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, CNW brings
its clients unparalleled visibility, recognition and brand
awareness. CNW is where news, content and information converge.
Receive Text Alerts
from CannabisNewsWire: Text "Cannabis" to
21000
For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the
CannabisNewsWire website applicable to all content provided by CNW,
wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by CNW are
solely those of CNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable CNW for any investment
decisions by their readers or subscribers. CNW is a news
dissemination and financial marketing solutions provider and is NOT
registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, CNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CNW undertakes no
obligation to update such statements.
Source:
CannabisNewsWire
Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
Wildflower Brands (CSE:SUN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Wildflower Brands (CSE:SUN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
